Identification of RPS6KA1 as novel molecular target of rhabdomyosarcoma
| Project/Area Number |
24791078
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
MIYACHI Mitsuru 京都府立医科大学, 医学(系)研究科(研究院), 助教 (40584983)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | RPS6KA1 / 横紋筋肉腫 / 分子標的療法 |
|---|
| Research Abstract |
We compared the expression pattern of mouse myoblasts which express rhabdomyosarcoma-specific fusion gene and identified the candidate gene as Rps6ka1. We examined rhabdomyosarcoma tumor specimens and found that RPS6KA1 is overexpressed compared with normal human skeletal muscle. RPS6KA1 inhibitor, BI-D1870, inhibited the proliferation of rhabdomyosarcoma cells and G2/M cell cycle arrest was observed. BI-D1870 treatment induced Myosin Heavy Chain expression and differentiation of rhabdomyosarcoma cells. RPS6KA1 may be a novel therapeutic target of rhabdomyosarcoma.
|
Report
(3 results)
Research Products
(3 results)
